Clinical trials: Dose Administration Aids
HIV Infections, Tuberculosis
A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV
Because drugs used to treat TB can reduce the amount of the anti-HIV drugs that reach the sites where the virus is located, this study is designed to see whether it is necessary to use higher doses of antiviral (anti-HIV) drugs…
- Trial name
- OPTI-NNRTI (NCT00523458)
- Testing
- efavirenz or nevirapine
- Where
- Brazil
- Volunteers
- 5 people
- Sponsor
- Stanford University
Human Immunodeficiency Virus
First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS
This first clinical study of 10-1074-LS will evaluate its safety, tolerability and pharmacokinetics profile when administered alone or in combination with 3BNC117-LS to HIV (human immunodeficiency virus) -infected and…
- Trial name
- NCT03554408
- Testing
- 10-1074-LS, 3BNC117-LS
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
HIV-1-infection
Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age
To assess patient reported treatment satisfaction and medication tolerability in virologically suppressed HIV-1 infected adults who are at least 65 years of age who switch to a bictegravir/emtricitabine/tenofovir alafenamide…
- Trial name
- NCT05147740
- Testing
- B/F/TAF
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Tulika Singh, MD
HIV
Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus
To investigate the effects of food and dose regimen on the antiviral effects of Maraviroc (UK-427,857) in patients with human immunodeficiency virus (HIV)
- Trial name
- NCT00634959
- Testing
- Maraviroc (UK-427,857)
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 37 people
- Sponsor
- ViiV Healthcare
Acquired Immunodeficiency Syndrome, Anemia
A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in Patients With Acquired Immunodeficiency Syndrome (AIDS) Who Are Receiving Zidovudine (AZT) Therapy
The purpose of this study is to evaluate the effectiveness and safety of epoetin alfa in AIDS patients for the treatment of anemia that is a result of the disease and zidovudine (AZT) treatment.
- Trial name
- NCT00270283
- Testing
- epoetin alfa
- Volunteers
- 102 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
HIV Infections
A Clinical Trial of Alternating and Intermittent Regimens of 2',3'-Dideoxycytidine and 3'-Azido-3'-Deoxythymidine in the Treatment of Patients With AIDS and Advanced ARC
To determine if alternating zidovudine (AZT) and zalcitabine (dideoxycytidine; ddC) (first one and then the other) or intermittent therapy (1 week of drug then 1 week off) will lessen the toxic effects of either drug alone, while…
- Trial name
- NCT00000718
- Testing
- Zidovudine, Zalcitabine
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment
The purpose of this study is to test the safety and effectiveness of a new non-nucleoside reverse transcriptase inhibitor (NNRTI), (+)-calanolide A, in HIV-positive patients who have never received anti-HIV treatment.
- Trial name
- NCT00002243
- Testing
- Calanolide A
- Where
- 9 sites in United States
- Volunteers
- 32 people
- Sponsor
- Sarawak MediChem Pharmaceuticals
HIV Infections
Safety and Effectiveness of Giving Adefovir (Preveon) Plus Other Anti-HIV Drugs to HIV-Infected Patients Who Have Not Responded to Other Anti-HIV Drug Combinations
The purpose of this study is to see if it is safe and effective to give adefovir plus other anti-HIV drugs to HIV-infected patients who have failed other anti-HIV drug combinations.
- Trial name
- NCT00002398
- Testing
- Levocarnitine, Adefovir dipivoxil
- Where
- United States
- Sponsor
- Gilead Sciences
Acquired Immunodeficiency Syndrome, HIV Infections
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir…
- Trial name
- NCT01565850
- Testing
- D/C/F/TAF, DRV, COBI
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 153 people
- Sponsor
- Gilead Sciences
HIV Infections
A Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Participants Without HIV
The study aims to evaluate the safety, tolerability and pharmacokinetic (PK) properties of a single dose of VH5356136 in adult participants without human immunodeficiency virus (HIV).
- Trial name
- NCT07822477
- Testing
- VH5356136 Formulation 1, VH5356136 Formulation 2
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects
To conduct a randomized dose-ranging study to evaluate the safety and activity of orally administered low dose interferon alfa-n3 as an immunomodulator in subjects with asymptomatic HIV-1 infection.
- Trial name
- NCT00215852
- Testing
- Alferon LDO
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- AIM ImmunoTech Inc.
HIV Infections
A Dose Response and Safety Study of Procaine HCl in HIV-Infected Patients
This a Phase I/II non-randomized, open-label clinical study of 8 weeks duration using SP01A in HIV positive patients on a stable antiretroviral regimen.
- Trial name
- NCT00299338
- Testing
- SP01A
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Samaritan Pharmaceuticals, Inc
HIV Infections
TMC114-C227: A Study to Evaluate the Effectiveness and Safety of TMC114 (Darunavir) With a Low Dose of Ritonavir as Monotherapy (no Other Anti-HIV Drugs Will be Given) in Patients Who Have Never Been Treated With Antiretrovirals (Anti-HIV Drugs) Previously
This is an open label study (no placebos are used; all patients will receive the true medication) to evaluate the effectiveness of TMC114/rtv in treatment naÃ-ve (never previously received anti-HIV drugs), HIV 1 infected patients.
- Trial name
- NCT00513513
- Testing
- TMC114 (darunavir) / ritonavir
- Volunteers
- 7 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infection
An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients
The objective of the study is to compare two doses of MVA-nef vs. MVA-BN to induce Nef-specific cellular immune response in HIV-1 infected patients
- Trial name
- NCT00189930
- Testing
- MVA-nef, IMVAMUNE
- Where
- 5 sites in Germany
- Volunteers
- 77 people
- Sponsor
- Bavarian Nordic
Cryptosporidiosis, HIV Infections
Treatment of Chronic Cryptosporidiosis in AIDS Patients
The purpose of this study is to see if it is safe and effective to add interleukin-12 (IL-12) to the standard drug combination (paromomycin plus azithromycin) used to treat cryptosporidiosis in AIDS patients.
- Trial name
- NCT00001128
- Testing
- Interleukin-12, Paromomycin sulfate, Azithromycin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Study of Single IV Administration of P2G12
A randomised phase I trial of a monoclonal antibody which neutralises HIV-1 (P2G12) to be given as a single intravenous infusion to healthy human volunteers to assess the safety and reactogenicity
- Trial name
- FuturePharma (NCT02923999)
- Testing
- P2G12 Dose Cohort 1, P2G12 Dose Cohort 2, P2G12 Dose Cohort 3
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- St George's, University of London
HIV Infections
A Multicenter Dose Ranging Clinical Trial of 2',3'-Dideoxycytidine in the Treatment of Patients With AIDS and Advanced ARC.
To evaluate the long-term safety and effectiveness of the drug 2',3'-dideoxycytidine ( zalcitabine; ddC ) in treating patients with AIDS or advanced AIDS related complex ( ARC ).
- Trial name
- NCT00000704
- Testing
- Zalcitabine
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lymphoma, Non-Hodgkin, HIV Infections
A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma
To determine the impact of dose intensity on tumor response and survival in patients with HIV-associated non-Hodgkin's lymphoma (NHL). HIV-infected patients are at increased risk for developing intermediate and high-grade NHL.
- Trial name
- NCT00000658
- Testing
- Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride
- Where
- 22 sites in United States
- Volunteers
- 250 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 Hours
Tipranavir is a drug with a high antiretroviral activity, also in presence of major mutations in the protease gene. However, its necessity of being co-administered with 400 mg of ritonavir daily, limits its efficacy for the…
- Trial name
- NCT00607958
- Testing
- tipranavir/ritonavir (dose reduction)
- Where
- Spain
- Volunteers
- 11 people
- Sponsor
- Germans Trias i Pujol Hospital
HIV Infection, Tuberculosis
Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV
There is a rapidly-growing need to identify evidence-based, safe, and effective co-treatment regimens for HIV-related tuberculosis (TB) among patients who require protease inhibitor (PI)-based antiretroviral therapy (ART).
- Trial name
- NCT01601626
- Testing
- Standard-dose Lopinavir/Ritonavir, Double-dose Lopinavir/Ritonavir, Raltegravir
- Where
- 9 sites in Brazil, Haiti and 3 more
- Volunteers
- 71 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections